Fenix Research Labs

Fenix Research Labs Private Limited, formerly known as Incozen Therapeutics, is a formulation-focused pharmaceutical R&D company and contract research organization (CRO) based in Hyderabad, India. The company specializes in developing next-generation drug delivery systems, advanced drug formulations, and analytical solutions, utilizing an innovative AI-based product selection approach to optimize development pathways. Historically, as Incozen, the company operated as an oncology-focused biotech specializing in the discovery and development of small-molecule cancer therapeutics, notably co-developing the dual PI3K delta/gamma and SIK3 inhibitor Tenalisib (RP6530) in collaboration with Rhizen Pharmaceuticals. Today, Fenix Research Labs provides integrated formulation, analytical, and pre-clinical development services to global pharmaceutical and biotech partners.